A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients
| Autor: | M. Cuttica, E. Porcella, A. Carraro, Massimo Giusti, G. Giordano, S. Valenti |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Adult
Galactorrhea medicine.medical_specialty Cabergoline Endocrinology Diabetes and Metabolism medicine.medical_treatment Dopamine Agents Administration Oral Dopamine agonist Gastroenterology Endocrinology Internal medicine Humans Medicine Ergolines Chemotherapy Dose-Response Relationship Drug business.industry Quinagolide Middle Aged Crossover study Prolactin Hyperprolactinemia Tolerability Aminoquinolines Female medicine.symptom business medicine.drug |
| Zdroj: | Journal of Endocrinological Investigation. 17:51-57 |
| ISSN: | 1720-8386 0391-4097 |
| Popis: | Cabergoline and quinagolide, two new dopamine agonist drugs with long-lasting activity, are currently under investigation for the treatment of hyperprolactinemia. At present, studies comparing these drugs for tolerability and efficacy in the same patients are lacking. It was our aim to make such a comparison in an open randomized cross-over trial. Cabergoline (0.5 mg twice weekly) and quinagolide (75 µg once daily) were given orally. Each drug was administered for 12 weeks. Treatment with the second drug was started after the recurrence of hyperprolactinemia. Twelve women with hyperprolactinemia due to idiopathic disease (n=6), microprolactinoma (n=5) or postsurgical empty sella (n=1) were evaluated. Six women were amenorrheic and 6 were oligomenorrheic. Ten had spontaneous or provoked galactorrhea. Baseline characteristics (age, clinical signs and PRL levels) of patients initially allocated to the two treatment groups were similar. Nine patients completed both treatment cycles and PRL levels were lower under cabergoline (10.7±3.7 µg/L) than under quinagolide (25.0±7.7 µg/L; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink